objective To understand Zika virus (ZIKV) dynamics in fluids of infected individuals and the risk of sexual transmission.
Introduction
Zika virus (ZIKV) is responsible for the recent pandemic in the American continent, affecting more than 50 countries in less than a year [1, 2] . Described in 1947 in a rhesus monkey in Uganda [3] , it received little attention until 2007 and 2013, when it caused major epidemics in the Pacific region [4, 5] .
ZIKV infection is mostly transmitted by the bite of an infected mosquito (Aedes species), but sexual transmission and mother-to-child transmission have also been described [6] . Other ways of transmission through blood transfusion or organ transplantation are highly probable [7] [8] [9] . ZIKV infection is related to an increased risk of neurological complications and adverse foetal outcomes.
Knowledge of ZIKV dynamics in human body fluids and its potential to be sexually transmitted is scarce. To date, transmission through semen or female genital tract fluids has been described [10] . By contrast, saliva has not been proved to be involved in human-to-human transmission, despite the detection of ZIKV ribonucleic acid (RNA) and isolation of the virus in saliva of infected individuals [11] . ZIKV RNA detection from semen persists generally longer than in other human body fluids and with higher viral load, probably due to a virus sanctuary or reservoir in the genital tract [12] . The contribution of ZIKV sexual transmission to the burden of the disease seems to be small [13] , but it may play an important role in spreading ZIKV infection in non-endemic Aedes-established regions.
Little is known regarding the risk of sexual transmission to an uninfected sexual partner. It seems reasonable that the viral load in genital tract fluids, type and frequency of sexual contacts may modify this risk [12] . To date, WHO international recommendations in regions with no active ZIKV transmission suggest sexual abstinence or safer sex practices for at least 6 months after returning from ZIKV transmission areas and for the whole duration of the pregnancy in the case of pregnant women with traveller sexual partners [10] .
The aim of our study was to assess the dynamics of ZIKV in several fluids of ZIKV-infected individuals through RNA detection and to determine the risk of sexual transmission to non-traveller sexual partners in a non-endemic area.
Methods

Study design
We conducted a prospective study at two centres of the International Health Program of the Catalan Institute of Health (PROSICS). Patients with probable or confirmed diagnosis of ZIKV infection (traveller patients) were clinically followed up, and fluid samples were collected from saliva, blood, urine and semen or vaginal secretion following the protocol. Patients were withdrawn from the study when all fluids were negative for ZIKV RNA detection.
Patients were asked about their sexual history from 1 week before symptoms onset to the medical visit date. All their sexual partners within this period were offered to participate (sexual contacts).
Ethics
The study protocol was approved by the institutional review board at Vall d'Hebron Teaching Hospital, Barcelona. All patients, including the sexual contact, were adults, consented to participate and signed the written consent form. All procedures were in concordance with the principles laid down at the last version of the Helsinki Declaration.
Patients
Traveller patients were eligible to participate if they met the following criteria: (i) age at least 18 years; (ii) recent travel history to an area with ongoing ZIKV transmission; (iii) symptoms or signs compatible with ZIKV infection; (iv) a positive result in any of the following tests: IgG for ZIKV, IgM for ZIKV or ZIKV RNA from any body fluid. Exclusion criteria were as follows: (i) refusal to consent; (ii) inability to attend the follow-up visits; (iii) plans to travel to a ZIKV-endemic area during the study period.
Sexual contacts were eligible to participate if they were at least 18 years old and had a sexual relation of any kind with a ZIKV-infected traveller patient 7 days before the initiation of the symptoms or at any time after. Exclusion criteria were refusal to consent and recent travel to an area with ongoing ZIKV transmission.
Study protocol
At the time of the diagnosis, a blood sample and mouth swab were taken. The mouth swab was self-collected after careful explanation by study investigators: patients were instructed to swab the inside of the cheek for approximately 1 min on each side (swab collector Deltaswab â Deltalab, S.L., Rub ı, Spain). We also collected midstream urine samples and semen (in sterilised collector) or vaginal swab samples (self-collected after careful explanation by study investigators with swab collector Deltaswab â Deltalab, S.L., Rub ı, Spain). Serological tests were performed on the serum samples, and ZIKV reverse transcription-polymerase chain reaction (RT-PCR) was performed on serum, saliva, urine and semen/vaginal swab samples. Patients who tested positive for ZIKV RNA were asked for fresh blood, saliva, urine and genital tract samples every 4 weeks until they tested negative.
Sexual contacts were interviewed, and data regarding sexual relations were elicited through a structured questionnaire. A blood sample was extracted from sexual contacts and serum-tested for ZIKV antibodies. If a positive result was obtained, we collected samples from blood, saliva, urine and semen/vaginal swab for ZIKV RNA detection.
All patients were instructed during the first visit about ZIKV transmission routes with a focus on how to prevent ZIKV sexual transmission and were advised to take safer sex practices.
Laboratory procedures
Serological testing. Detection of specific IgM and IgG antibodies against ZIKV, dengue virus (DENV) and chikungunya (CHKV) virus was made through immunofluorescence assay (IIFT, Arboviral fever Mosaic, Euroimmun, Luebeck, Germany) according to the manufacturer 0 s instructions. All serum samples were previously diluted 1:10 in sample buffer for IgG detection and the same dilution (1:10) using an immunosorbent (EURO-SORB, Euroimmun, Luebeck, Germany) for IgM assay. The qualitative evaluation of results was made in a fluorescent microscope (450-490 nm) by an experimented observer.
Neutralising antibody titres against ZIKV were determined using a plaque reduction neutralisation test (PRNT) with a 90% cut-off value follow standard methods.
RT-PCR procedure. Total nucleic acids were extracted from 400 ll and eluted in 25 ll using NucliSens easy-MAG (Biomerieux. Marcy l'Etoile, France) according to the manufacturer's instructions and kept frozen until use. Two commercial real-time specific RT-PCR assays, LightMix Modular Zika Virus (TIB MolBiol, Berlin, Germany/ Roche, Switzerland) and RealStarâ Zika Virus RT-PCR Kit 1.0 (Altona Diagnostics, Hamburg, Germany), were performed at two time points. Initially, LightMix Modular Zika Virus was used from January to June 2016, then the RealStarâ Zika Virus RT-PCR Kit 1.0 from June to December 2016. Samples were amplified and detected in a thermocycler SmartCycler (Cepheid, Sunnyvale, CA, USA), or CFX96 real-time system (Bio-Rad, Hercules, CA, USA)). A sample was considered positive when the threshold (Ct) was <40. The amplification cycle threshold (Ct) was used as an indirect marker of viral load.
Results
From January 2016 to December 2016, we included a total of 11 traveller patients and six sexual contacts. Six of 11 (54.5%) patients were male. The median age was 38 (IQR 30-45) years. The main reason to travel was visiting friends and relatives (six patients), followed by tourism. The median time of trip duration was 24 (IQR 11-34) days (Table 1) .
The most frequent symptoms and signs of the patients were fever (100%), rash (81.8%), arthralgias (72.7%), myalgias (36.4%), headache (27.3%), conjunctivitis (18.2%), diarrhoea (18.2%), abdominal pain (9.1%), somnolence (9.1%), sore throat (9.1%) and asthenia (9.1%). The median duration of the symptoms was 5 (IQR 4-7) days. Laboratory procedures were performed 11 (IQR 3-31) days after symptoms onset. Six patients had sexual relations during the defined period, two of them travelled with the index-infected case and therefore were not eligible, and one patient never came to our centre after telephonic contact. Accordingly, three sexual contacts could be studied. Each of them had only one sexual relation with the index case ( Table 2 ) before entering the study protocol. All sexual contacts included had sexual relations with index cases who tested negative for ZIKV RNA in genital tract fluids. All tested negative for ZIKV infection through serological tests ( Table 2) .
Nine of 11 patients were diagnosed with a positive ZIKV IgM or positive ZIKV RNA RT-PCR. Two patients had only a positive ZIKV IgG, one of them with concomitant positive DENV IgG and yellow fever vaccination history; however, a neutralisation study was carried out and resulted positive. This patient became pregnant during the symptomatic phase of the infection.
We performed a total of 61 RT-PCR determinations; seven were positive. We retrieved positive results from serum, urine, semen and vaginal tract but did not have any positive result from saliva even in patients with positive results in other fluids. In five patients, RT-PCR procedures could be carried out during the first 7 days after symptoms onset, and 40% had at least one positive result. Vaginal swabs were collected in all five women included in the study. Four of them had the vaginal swab collected during the first 45 days after the symptoms onset. Only one of these four women had a positive ZIKV RNA detection in the genital tract fluids for 37 days after the onset of the symptoms. Between day 37 and day 69 after symptoms onset, the virus was cleared from vaginal secretions.
Five male patients provided semen samples during the first 45 days after symptoms onset and one of them tested positive for ZIKV RNA until day 23 after symptoms onset. Clearance occurred between day 23 and 107 after symptoms onset.
Serological results for ZIKV and other arboviral infections in Table 3 , along with ZIKV RNA detection results, show that all patients with positive ZIKV RT-PCR showed positive ZIKV IgG. Nine patients had serological results beyond the 30 days after the onset of the symptoms; two had both tests (ZIKV IgM and ZIKV IgG) negative, three had both tests positive and four showed a negative ZIKV IgM and positive ZIKV IgG. Patients with both negative tests beyond 30 days had no positive RT-PCR ZIKV in any sample.
Discussion
Despite no longer being a global public health emergency [14] , ZIKV infection still remains a global threat due to its potential to cause severe neurological complications and poor foetal outcomes in pregnant women [15] [16] [17] [18] . The WHO report, December 2016, showed 13 countries with evidence of person-to-person transmission [19] . In this prospective study, we report our findings on ZIKV dynamics in body fluids from ZIKV-infected travellers in a non-endemic country and assess the risk of sexual transmission to their sexual partners. Nine of 11 (81.1%) patients were diagnosed based on positive ZIKV IgM or positive ZIKV RNA detection. One of four women had ZIKV RNA detection in vaginal swab during the first 45 days after symptoms onset. Similarly, ZIKV RNA was detected in semen in one of five men during the first 45 days after symptoms onset. We did not find any sexual transmission of ZIKV in our study.
ZIKV is the first flavivirus to be sexually transmitted in humans. To date, male-to-female, male-to-male and female-to-male sexual transmission has been described with several sexual routes involved including vaginal sex, anal sex and probably oral sex with ejaculation [20, 21, 22] The few data available come from case reports from symptomatic returning travellers who infected their sexual partners; ZIKV sexual transmission from non-symptomatic patient has only been reported in two cases and always involving male-to-female transmission [23, 24] .
In our study, we did not identify any sexual transmission among the investigated sexual partners by serological testing. We fully investigated three sexual practices, 
Neg, negative; RT-PCR, reverse transcription-polymerase chain reaction; SP, sexual partner. Grey shadding reflects patients who had sexual relations with the index patients, but were not eligible or never came to the outpatient office to participate in the study. two of them oral sex without oral ejaculation and one insertive sex without any protection. None of the ZIKVinfected patients who reported sexual practices had ZIKV RNA detection in genital tract fluids and this may reflect relatively low exposure to produce an infection in the sexual partner, as sexual transmission has been correlated with viral shedding in the genital tract [12, [25] [26] [27] [28] . However, transmission with low viral load in semen, late transmission, and transmission in asymptomatic travellers has been described [23, 27] . The minimum infectivity threshold for sexually transmitted infections has yet to be elucidated, but it is likely that patients with no ZIKV RNA detection in semen with the current tests have very low risk to sexually transmit the infection. As it has been demonstrated in other sexually transmitted infections, the type of sexual contact might be associated with the likelihood of ZIKV sexual transmission. This may partially explain the higher number of reports of male-to-female transmission.
The contribution of sexual transmission to the global burden of ZIKV infection in endemic areas is difficult to assess, but it has been suggested that sexual transmission contributed around 3% to the basic reproduction rate [13, 29] . In patients diagnosed with ZIKV infection outside an endemic country <1% acquired the infection through sexual contact [30] . Sexual transmission by its own will not be able to sustain ZIKV infection in the community [13] but could impede control of the disease and play an important role in the introduction of the virus in non-endemic Aedes-containing countries.
Although our study included a small number of patients, we found that one of four and one of five of the female and male, respectively, had a positive ZIKV RNA detection in genital tract fluids the first 45 days after symptoms onset. Two recent manuscripts prospectively studied ZIKV in body fluids, one in an endemic area and the other in a non-endemic area, reporting 56.4% and 62.5% of ZIKV RNA detection in semen from patients with RT-PCR-confirmed infection, being lower in patients if serologically confirmed infection [28, 31] . The median and 95th percentiles for ZIKV clearance in semen from RT-PCR-confirmed patients in an endemic area were 34 days and 81 days, respectively [28] .
In non-pregnant ZIKV-infected patients, the genital tract is the place where ZIKV RNA has been detected for longer periods of time, even after clearance from blood and urine. [32] [33] [34] The genital tract acts as a sanctuary for ZIKV survival, allowing and extending the risk of sexual transmission. Whether this sanctuary sheds ZIKV back to the blood stream, being infective to the mosquito, is an unsolved question with huge public health repercussions. Reasons for persistence are unknown, but factors such as viral load inoculation, previous flavivirus infections and host-virus interaction should be taken into account. The latest date of sexual transmission after symptoms onset has been a case of male-to-female transmission at 41 days [27] , while the longest time of ZIKV RNA detection in semen is 188 days [33] , and the longest time for ZIKV isolation from semen is 24 days [26] . ZIKV persistence in the female tract is of utmost importance as it could be implicated in woman-to-man transmission and could yield adverse pregnancy outcomes even weeks after the end of the symptoms. In women, the maximum ZIKV RNA detection period in genital tract fluids was been 14 days [35] . In our study, we were able to detect ZIKV from a vaginal swab 37 days after symptoms onset. ZIKV dynamics information is coming mainly from mosquito-borne infections of symptomatic patients; viral dynamics knowledge is lacking in non-vectorial transmission infections and asymptomatic patients. Serology is the method of choice for the diagnosis of flaviviruses; however, its use in ZIKV infection raises some concern. ZIKV serology dynamics seem to be more chaotic than in other arboviral diseases. Additionally, cross-reactivity with other flaviviruses poses a major constraint. CDC recommendations on ZIKV diagnosis in non-pregnant symptomatic patients with an exposure history rely on serum and urine RT-PCR from specimens collected within 14 days after symptoms onset. If a negative RT-PCR result is retrieved from serum and urine specimens, then IgM antibody against ZIKV and DENV should be investigated [36] . According to CDC guidelines, serum specimens collected from 7 days to 12 weeks after symptoms onset with negative ZIKV and DENV IgM discard either infection. Based on our results, ZIKV IgM is of limited use, and in some patients with ZIKV RNA detection, it never becomes positive. However, the CDC recommendation is to use ZIKV IgM antibody capture enzyme-linked immunosorbent assay, while in our study, we used IIFT.
ZIKV IgM should be used with caution, and interpretation should be done gathering all available information including IgM and IgG antibodies against ZIKV and DENV and RNA ZIKV from body fluids, including genital tract fluids. It may be wise to recommend semen or female genital tract fluids RNA ZIKV detection to study ZIKV infection in symptomatic patients at any time, especially beyond the first 2 weeks when other fluids have become negative [12, 37] . We therefore advocate review of the diagnostic procedures and propose that the diagnosis includes RT-PCR tests from several body fluids, including genital tract fluids and whole blood better than serum [35] . At least two samples of genital tract fluids should be collected before excluding infection due to false-negative results [38] .
WHO recommends that in areas with ongoing ZIKV transmission, all people regardless of their sex should receive information about ZIKV infection, be offered counselling on safer sexual practices and be provided access to family control programmes. In areas without ongoing ZIKV transmission, travellers returning from ZIKV-endemic areas should adopt safer sexual practices or sexual abstinence for at least 6 months upon arrival and during the whole duration of pregnancy if they are pregnant or having sexual relations with a pregnant woman. Child-bearing females or their partners returning from ZIKV-endemic areas looking for pregnancy are advised to wait at least 6 months to ensure ZIKV clearance from the genital tract fluids [10] . CDC recommendations for females are laxer and recommend 8 weeks of abstinence or safer sex practices [39] . We deem that the patients with negative results in serum, urine, saliva and genital tract fluids may have very low risk of transmitting the infection to a sexual partner; however, more data are needed. Out of an abundance of caution and according to our data, preventing sexual relations in all travellers to ZIKV-endemic areas during a prudent 6-month period of time would avert sexually transmitted infections and imperfect foetuses in the majority of cases.
Our study has some limitations. Firstly, the small number of patients recruited precludes us from having a wider view of ZIKV dynamics. Detection of ZIKV RNA is the preferred diagnostic method, some of our patients had serological diagnosis; however, they have symptoms compatible with the disease, visited countries with ZIKV ongoing transmission and had other arboviral infections excluded. Secondly, the interval between sample collections limits our accuracy to model ZIKV dynamics. As mentioned before, false-negative results in semen have been reported, so it could be possible that some of our patients could show positive results with repeated samples. We detected ZIKV RNA, but did not determine the viability of the virus in culture, precluding us from associating detection with infectivity. Many patients were aware of the WHO recommendations about sexual abstinence or safer sex practices after a suspicion of ZIKV infection and this may partially explain the low number of sexual episodes recorded, added to the fact that ZIKV sexual transmission is a rare occurrence. Therefore, sexual transmission could only be partially investigated, and efficiency of sexual transmission poorly assessed. All index partners investigated tested negative for ZIKV RNA in genital tract fluids; also, sexual relations were few and heterogeneous. Nevertheless, it may confirm that ZIKV informative public health campaigns are being effective. Our findings are based on symptomatic patients; however, the majority of infected patients would remain asymptomatic. The virus dynamics and risk of sexual transmission in this population are completely unknown, as is the incidence of complications [23] . However, ZIKV dynamics in ZIKV-endemic areas are difficult to assess due to the impossibility of disentangling exposure via mosquito from sexual exposure.
In summary, we observed ZIKV persistence in genital tract fluids in one of four infected women and one of five infected men within 45 days after symptoms onset. The clearance time was beyond 37 days for the female patients and 24 days for the male patients. Sexual transmission to sexual contacts from ZIKV-infected travellers was not detected, probably because of the high awareness of sexually transmitting the infection to not infected sexual partners. Diagnostic algorithms could be updated to include genital tract fluid specimens in the diagnostic process. Further research with bigger cohorts of patients with ZIKV infection is needed to better understand ZIKV dynamics and help public health agencies to inform more accurate and evidence-based guidelines.
